Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 8
1981 36
1982 38
1983 50
1984 35
1985 61
1986 69
1987 55
1988 79
1989 76
1990 73
1991 87
1992 102
1993 93
1994 93
1995 108
1996 94
1997 100
1998 105
1999 105
2000 125
2001 148
2002 144
2003 142
2004 181
2005 197
2006 193
2007 228
2008 277
2009 375
2010 363
2011 388
2012 423
2013 533
2014 832
2015 847
2016 810
2017 817
2018 865
2019 979
2020 1245
2021 1463
2022 1522
2023 1678
2024 551

Text availability

Article attribute

Article type

Publication date

Search Results

14,667 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for M. ag nia
Search for M. Aghnia instead (1 results)
Genetic drivers of m(6)A methylation in human brain, lung, heart and muscle.
Xiong X, Hou L, Park YP, Molinie B; GTEx Consortium; Gregory RI, Kellis M. Xiong X, et al. Nat Genet. 2021 Aug;53(8):1156-1165. doi: 10.1038/s41588-021-00890-3. Epub 2021 Jul 1. Nat Genet. 2021. PMID: 34211177 Free PMC article.
We integrate m(6)A QTLs with disease genetics, identifying 184 GWAS-colocalized m(6)A QTL, including brain m(6)A QTLs underlying neuroticism, depression, schizophrenia and anxiety; lung m(6)A QTLs underlying expiratory flow and asthma; and muscle/heart …
We integrate m(6)A QTLs with disease genetics, identifying 184 GWAS-colocalized m(6)A QTL, including brain m(6)A QTLs u …
Meaningful change and responsiveness in common physical performance measures in older adults.
Perera S, Mody SH, Woodman RC, Studenski SA. Perera S, et al. J Am Geriatr Soc. 2006 May;54(5):743-9. doi: 10.1111/j.1532-5415.2006.00701.x. J Am Geriatr Soc. 2006. PMID: 16696738
Most substantial change estimates ranged from 0.08 to 0.14 m/s for gait speed, 0.99 to 1.34 points for SPPB, and 47 to 49 m for 6MWD. ...CONCLUSION: Best initial estimates of small meaningful change are near 0.05 m/s for gait speed, 0.5 points for SPPB, and 2 …
Most substantial change estimates ranged from 0.08 to 0.14 m/s for gait speed, 0.99 to 1.34 points for SPPB, and 47 to 49 m fo …
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE; Guideline Subcommittee of the AAN. Pringsheim T, et al. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. Neurology. 2021. PMID: 34782410 Free PMC article. Review.
RESULTS: Initial treatment with levodopa provides superior motor benefit compared to treatment with dopamine agonists, whereas levodopa is more likely than dopamine agonists to cause dyskinesia. The comparison of different formulations of dopamine agonists yi …
RESULTS: Initial treatment with levodopa provides superior motor benefit compared to treatment with dopamine agonists, whereas levodo …
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Gratuze M, Schlachetzki JCM, D'Oliveira Albanus R, Jain N, Novotny B, Brase L, Rodriguez L, Mansel C, Kipnis M, O'Brien S, Pasillas MP, Lee C, Manis M, Colonna M, Harari O, Glass CK, Ulrich JD, Holtzman DM. Gratuze M, et al. Neuron. 2023 Jan 18;111(2):202-219.e7. doi: 10.1016/j.neuron.2022.10.022. Epub 2022 Nov 10. Neuron. 2023. PMID: 36368315 Free PMC article.
β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.
Slosky LM, Bai Y, Toth K, Ray C, Rochelle LK, Badea A, Chandrasekhar R, Pogorelov VM, Abraham DM, Atluri N, Peddibhotla S, Hedrick MP, Hershberger P, Maloney P, Yuan H, Li Z, Wetsel WC, Pinkerton AB, Barak LS, Caron MG. Slosky LM, et al. Cell. 2020 Jun 11;181(6):1364-1379.e14. doi: 10.1016/j.cell.2020.04.053. Epub 2020 May 28. Cell. 2020. PMID: 32470395 Free PMC article.
Small molecule neurotensin receptor 1 (NTSR1) agonists have been pursued for more than 40 years as potential therapeutics for psychiatric disorders, including drug addiction. Clinical development of NTSR1 agonists has, however, been precluded by their severe side ef …
Small molecule neurotensin receptor 1 (NTSR1) agonists have been pursued for more than 40 years as potential therapeutics for psychia …
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Dave CV, et al. Ann Intern Med. 2019 Aug 20;171(4):248-256. doi: 10.7326/M18-3136. Epub 2019 Jul 30. Ann Intern Med. 2019. PMID: 31357213 Free PMC article.
OBJECTIVE: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists. DESIGN: Population-b …
OBJECTIVE: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those i …
Genetic Evidence Supporting a Causal Role of Depression in Alzheimer's Disease.
Harerimana NV, Liu Y, Gerasimov ES, Duong D, Beach TG, Reiman EM, Schneider JA, Boyle P, Lori A, Bennett DA, Lah JJ, Levey AI, Seyfried NT, Wingo TS, Wingo AP. Harerimana NV, et al. Biol Psychiatry. 2022 Jul 1;92(1):25-33. doi: 10.1016/j.biopsych.2021.11.025. Epub 2021 Dec 16. Biol Psychiatry. 2022. PMID: 35177243 Free PMC article.
Combinatorial interventions in aging.
Parkhitko AA, Filine E, Tatar M. Parkhitko AA, et al. Nat Aging. 2023 Oct;3(10):1187-1200. doi: 10.1038/s43587-023-00489-9. Epub 2023 Oct 2. Nat Aging. 2023. PMID: 37783817 Review.
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. Choi JG, et al. Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4. Ann Intern Med. 2022. PMID: 36191315 Free PMC article.
INTERVENTION: First-line SGLT2 inhibitors or GLP1 receptor agonists. OUTCOME MEASURES: Life expectancy, lifetime costs, incremental cost-effectiveness ratios (ICERs). ...Oral GLP1 receptor agonists were not cost-effective (ICER, $823 000 per QALY). To be cost-effect …
INTERVENTION: First-line SGLT2 inhibitors or GLP1 receptor agonists. OUTCOME MEASURES: Life expectancy, lifetime costs, incremental c …
Firearms and Dementia.
Betz ME, McCourt AD, Vernick JS, Ranney ML, Wintemute GJ. Betz ME, et al. Ann Intern Med. 2018 Nov 20;169(10):740. doi: 10.7326/L18-0523. Ann Intern Med. 2018. PMID: 30452572 Free PMC article. No abstract available.
14,667 results
You have reached the last available page of results. Please see the User Guide for more information.